Overview

Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to test a single dose of intranasal oxytocin, compared to placebo, in a within subjects, crossover design, to see if oxytocin will improve satiety signaling (behaviorally and/or by self report) compared to placebo. If this single dose pilot paradigm shows an increase in satiety, it may be tested in follow-up studies as a prevention or treatment for weight gain and overeating in people with schizophrenia.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland
University of Maryland, Baltimore
Treatments:
Oxytocin